全文获取类型
收费全文 | 37270篇 |
免费 | 2833篇 |
国内免费 | 1486篇 |
专业分类
耳鼻咽喉 | 271篇 |
儿科学 | 439篇 |
妇产科学 | 951篇 |
基础医学 | 8310篇 |
口腔科学 | 635篇 |
临床医学 | 2437篇 |
内科学 | 5522篇 |
皮肤病学 | 610篇 |
神经病学 | 1647篇 |
特种医学 | 1521篇 |
外国民族医学 | 3篇 |
外科学 | 1784篇 |
综合类 | 4626篇 |
现状与发展 | 5篇 |
预防医学 | 2919篇 |
眼科学 | 287篇 |
药学 | 3650篇 |
6篇 | |
中国医学 | 861篇 |
肿瘤学 | 5105篇 |
出版年
2024年 | 17篇 |
2023年 | 466篇 |
2022年 | 598篇 |
2021年 | 1049篇 |
2020年 | 1115篇 |
2019年 | 1003篇 |
2018年 | 922篇 |
2017年 | 1087篇 |
2016年 | 1208篇 |
2015年 | 1389篇 |
2014年 | 1991篇 |
2013年 | 2574篇 |
2012年 | 1805篇 |
2011年 | 2154篇 |
2010年 | 1766篇 |
2009年 | 1841篇 |
2008年 | 1802篇 |
2007年 | 1867篇 |
2006年 | 1804篇 |
2005年 | 1681篇 |
2004年 | 1594篇 |
2003年 | 1350篇 |
2002年 | 1204篇 |
2001年 | 1077篇 |
2000年 | 947篇 |
1999年 | 785篇 |
1998年 | 662篇 |
1997年 | 592篇 |
1996年 | 547篇 |
1995年 | 607篇 |
1994年 | 621篇 |
1993年 | 444篇 |
1992年 | 459篇 |
1991年 | 347篇 |
1990年 | 327篇 |
1989年 | 276篇 |
1988年 | 243篇 |
1987年 | 160篇 |
1986年 | 167篇 |
1985年 | 217篇 |
1984年 | 183篇 |
1983年 | 75篇 |
1982年 | 97篇 |
1981年 | 110篇 |
1980年 | 103篇 |
1979年 | 73篇 |
1978年 | 59篇 |
1977年 | 38篇 |
1976年 | 41篇 |
1973年 | 12篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
目的:分析子野个数限值对宫颈癌固定野调强放疗(fixed-field intensity-modulated radiotherapy,ff-IMRT)计划的影响,寻求最优的子野个数限值。方法:选取10例接受ff-IMRT的宫颈癌患者,基于Monaco 5.11.03计划系统,以45 Gy/25 f处方剂量分别对同一患者设计8种ff-IMRT计划(ff-IMRT计划依据子野个数限值命名,子野个数限值分别为40、60、70、80、100、120、130、150),采用SPSS 20.0软件比较除plan100之外7个ff-IMRT计划与plan100剂量学参数、优化时间和治疗参数的差异。结果:8种ff-IMRT计划归一化后,plan40和plan60的D2%、Dmin、CI和HI均劣于plan100(P<0.05)。8种ff-IMRT计划均能较好保护危及器官(organ at risk,OAR)和正常组织。plan40小肠V45;plan40和plan60小肠D2cc,直肠、膀胱V45、D40%,两侧股骨头V40和正常组织 V35、V40均高于plan100(P<0.05)。plan40和plan60优化时间、治疗参数均优于plan100(P<0.05);plan120、plan130和plan150子野面积、子野个数(51~150 cm2和>150 cm2)和出束时间均劣于plan100(P<0.05)。结论:子野个数限值为70~100时,ff-IMRT计划能兼顾剂量学参数满足临床要求、优化时间和治疗参数最优化,建议在设计宫颈癌ff-IMRT计划时在该范围内设置子野个数限值。 相似文献
2.
《Journal of vascular and interventional radiology : JVIR》2022,33(8):895-902.e4
PurposeTo study, from a U.S. payer’s perspective, the economic consequences of drug-coated balloon (DCB) versus standard percutaneous transluminal angioplasty (PTA) use for the treatment of stenotic lesions in dysfunctional hemodialysis arteriovenous fistulae.Materials and MethodsCost differences between DCBs and PTA at year 1 and beyond were calculated via 2 methods. The first approach used the mean absolute number of trial-observed access circuit reinterventions through 12 months (0.65 ± 1.05 vs 1.05 ± 1.18 events per patient for DCBs and PTA, respectively) and projected treatment outcomes to 3 years. The second approach was based on the trial-observed access circuit primary patency rates at 12 months (53.8% vs 32.4%) and calculated the cost difference on the basis of previously published Medicare cost for patients who maintained or did not maintain primary patency. Assumptions regarding DCB device prices were tested in sensitivity analyses, and the numbers needed to treat were calculated.ResultsUsing the absolute number of access circuit reinterventions approach, the DCB strategy resulted in an estimated per-patient savings of $1,632 at 1 year and $4,263 at 3 years before considering the DCB device cost. The access circuit primary patency approach was associated with a per-patient cost savings of $2,152 at 1 year and $3,894 at 2.5 years of follow-up. At the theoretical DCB device reimbursement of $1,800, savings were $1,680 and $2,049 at 2.5 and 3 years, respectively. The one-year NNT of DCB compared to PTA was 2.48.ConclusionsEndovascular therapy for arteriovenous access stenosis with the IN.PACT AV DCB can be expected to be cost-saving if longer follow-up data confirm its clinical effectiveness. 相似文献
3.
Lipid nanoparticles (LNPs) are becoming popular as a means of delivering therapeutics, including those based on nucleic acids and mRNA. The mRNA-based coronavirus disease 2019 vaccines are perfect examples to highlight the role played by drug delivery systems in advancing human health. The fundamentals of LNPs for the delivery of nucleic acid- and mRNA-based therapeutics, are well established. Thus, future research on LNPs will focus on addressing the following: expanding the scope of drug delivery to different constituents of the human body, expanding the number of diseases that can be targeted, and studying the change in the pharmacokinetics of LNPs under physiological and pathological conditions. This review article provides an overview of recent advances aimed at expanding the application of LNPs, focusing on the pharmacokinetics and advantages of LNPs. In addition, analytical techniques, library construction and screening, rational design, active targeting, and applicability to gene editing therapy have also been discussed. 相似文献
4.
5.
《Revista brasileira de otorrinolaringologia (English ed.)》2022,88(3):331-336
IntroductionThe association between the intensity of obstructive sleep apnea and skeletal alterations in the face and hyoid bone is still scarcely addressed in the literature.ObjectiveTo evaluate whether the intensity of obstructive sleep apnea is associated with craniofacial alterations and the position of the hyoid bone in children with mixed dentition.Methods76 children aged 7 to 10 years old were examined by otorhinolaryngological evaluation, polysomnography, and orthodontic assessment, including cephalometry. The participants were divided in 3 groups: primary snoring, mild obstructive sleep apnea and moderate to severe obstructive sleep apnea. Cephalometric measures of the face and hyoid bone were assessed. These measures were compared among the different groups by unpaired Student's t test. Moreover, these measures were correlated with the patient's obstructive apnea and hypopnea index variable using Pearson's correlation test.ResultsOf the 76 children, 14 belonged to group 1, with primary snoring; 46 to group 2, with mild obstructive sleep apnea; and 16 to group 3, with moderate-severe obstructive sleep apnea. There was no difference between the groups regarding the craniofacial variables. Children with obstructive sleep apnea showed a longer distance from the hyoid bone to the mandibular plane when compared to the primary snoring group (p < 0.05). Between the two obstructive sleep apnea subgroups, patients with moderate or severe disease showed significantly shorter horizontal distance between the hyoid bone and the posterior pharyngeal wall (p < 0.05), when compared to the groups with mild obstructive sleep apnea. We also observed a significant positive correlation between obstructive apnea and hypopnea index and the distance from the hyoid to the mandibular plane (p < 0.05) as well as a significant negative association between obstructive apnea and hypopnea index and the horizontal distance from the hyoid to the posterior pharyngeal wall (p < 0.01).ConclusionWe did not observe any association between obstructive sleep apnea and linear lateral alterations of the face. In contrast, there is a direct association between obstructive sleep apnea severity and the inferior and posterior position of the hyoid bone in children aged 7 to 10 years old. 相似文献
6.
7.
《Hematology/oncology and stem cell therapy》2021,14(4):267-274
Increasing trend in oral cancer (0.6% per year) and its related mortality has been reported worldwide since 2010. The United States alone reports an increase of 57% within the past 10 years. This emphasizes the need not only for designing strategies of prevention and planning but also for an effective treatment regime for the various oral cancers. Cancers of the lips, tongue, cheeks, floor of the mouth, and hard palate have been primarily classified under the category of oral cancers. If left undiagnosed, these cancers can be life threatening. Amongst these, the most undesignated and understudied cancer type is the lip carcinoma, which is either categorized under oral cancer or/as well as skin cancer or head and neck cancer. However, lip cancer corresponds to 25–30% of all diagnosed oral cancers. Though the etiology of lip cancer is not yet fully understood, numerous risk factors involved in its development are now being studied. The cells in the lip region are continuously exposed to various DNA damaging agents from endogenous as well as exogenous sources. Flaws in DNA repair mechanisms involved in eliminating these damages may be linked to the origin of carcinogenesis. Accumulation of DNA damage and defect in repair mechanisms may play a role in lip carcinogenesis and progression. This literature review is an exhaustive compilation of the research work performed on the role of DNA damage and repair responses in lip carcinoma which will pave a path for researchers to identify predictive DNA repair biomarker/s for lip cancer, and its diagnosis, prevention, and treatment. 相似文献
8.
【摘要】 目的 明确1个LEOPARD综合征家系的PTPN11基因突变。方法 对中国科学院大学宁波华美医院确诊的1例LEOPARD综合征先证者的家系进行现场调查。提取家系内4例患者、2例健康成员及与该家系无关的100例健康对照外周血标本。PCR扩增PTPN11基因所有外显子,使用Sanger测序法进行突变位点分析。结果 该家系3代14人,其中6人患病(男3例,女3例),符合常染色体显性遗传。患者皮损主要分布于面部、躯干和四肢,具有特殊面容及心血管系统异常。4例患者存在PTPN11基因的错义突变c.1632G>T(p.R558L),导致第558位由精氨酸变为亮氨酸,该突变既往未曾报道。该家系2例健康成员及100例健康对照未发现PTPN11基因突变。结论 该LEOPARD综合征家系患者PTPN11基因13号外显子发生c.1632G>T错义突变,可能是该家系患者发病的分子基础。 相似文献
9.
Kazuko Sakai Takayuki Takahama Mototsugu Shimokawa Koichi Azuma Masayuki Takeda Terufumi Kato Haruko Daga Isamu Okamoto Hiroaki Akamatsu Shunsuke Teraoka Akira Ono Tatsuo Ohira Toshihide Yokoyama Nobuyuki Yamamoto Kazuhiko Nakagawa Kazuto Nishio 《Molecular oncology》2021,15(1):126
The WJOG8815L phase II clinical study involves patients with non‐small cell lung cancer (NSCLC) that harbored the EGFR T790M mutation, which confers resistance to EGFR tyrosine kinase inhibitors (TKIs). The purpose of this study was to assess the predictive value of monitoring EGFR genomic alterations in circulating tumor DNA (ctDNA) from patients with NSCLC that undergo treatment with the third‐generation EGFR‐TKI osimertinib. Plasma samples of 52 patients harboring the EGFR T790M mutation were obtained pretreatment (Pre), on day 1 of treatment cycle 4 (C4) or cycle 9 (C9), and at diagnosis of disease progression or treatment discontinuation (PD/stop). CtDNA was screened for EGFR‐TKI‐sensitizing mutations, the EGFR T790M mutation, and other genomic alterations using the cobas EGFR Mutation Test v2 (cobas), droplet digital PCR (ddPCR), and targeted deep sequencing. Analysis of the sensitizing—and T790M—EGFR mutant fractions (MFs) was used to determine tumor mutational burden. Both MFs were found to decrease during treatment, whereas rebound of the sensitizing EGFR MF was observed at PD/stop, suggesting that osimertinib targeted both T790M mutation‐positive tumors and tumors with sensitizing EGFR mutations. Significant differences in the response rates and progression‐free survival were observed between the sensitizing EGFR MF‐high and sensitizing EGFR MF‐low groups (cutoff: median) at C4. In conclusion, ctDNA monitoring for sensitizing EGFR mutations at C4 is suitable for predicting the treatment outcomes in NSCLC patients receiving osimertinib (Clinical Trial Registration No.: UMIN000022076).
Abbreviations
- CIs
- confidence intervals
- ctDNA
- circulating tumor DNA
- ddPCR
- droplet digital PCR
- EGFR
- epidermal growth factor receptor
- MFs
- mutant fractions
- NGS
- next‐generation sequencing
- NSCLC
- non‐small cell lung cancer
- ORR
- overall response rate
- OS
- overall survival
- PD
- progressive disease
- PFS
- progression‐free survival
- PR
- partial response
- SD
- stable disease
- TKI
- tyrosine kinase inhibitor
10.
Skin cancer is the deadliest type of malignant disease and causes primary mortality worldwide. Dioscin, which exists in medicinal plants, has potent anticancer effects. However, its effects on skin cancer remain unknown. In the present study, the activity and mechanism of dioscin on the human skin cancer A431 cell line were investigated, MTT, colony formation, Transwell, wound-healing, TUNEL, Comet, immunofluorescence and western blot assays were used to assess the effects of dioscin on A431 cells. The results of MTT, colony formation, Transwell and wound-healing assays revealed that dioscin suppressed proliferation, colony formation and invasion of the cancer cells. TUNEL and comet assays demonstrated that dioscin exhibited significant effects on cell apoptosis and DNA damage. Investigations into the mechanism revealed that the expression levels of phosphorylated Ataxia telangiectasia-mutated (ATM) were considerably activated by dioscin, which significantly upregulated the expression levels of p53 to activate mitochondrial apoptosis signaling. Furthermore, the expression levels of BAX, cleaved caspase-3/9 and cleaved poly (ADP-ribose) polymerase were upregulated, and the expression levels of BCL-2 were downregulated by dioscin. Additionally, dioscin markedly downregulated the expression levels of matrix metalloproteinase 2 (MMP2), MMP9, RHO and cdc42, which are all associated with tumor invasion. In addition, p53-small interfering RNA transfection experiments indicated that dioscin exhibited excellent activity against skin cancer in vitro by decreasing p53 expression. Overall, the present results suggested that dioscin inhibited skin cancer cell proliferation via adjusting ATM/p53-mediated cell apoptosis, migration and DNA damage, which should be considered as a potential option for future treatments of skin cancer. 相似文献